Last reviewed · How we verify
BBC oral spray
BBC oral spray is a Small molecule drug developed by Hams Hamed Abdelrahman. It is currently in Phase 2 development for Mouth pain relief.
BBC oral spray is a topical anesthetic used to provide pain relief.
BBC oral spray is a topical anesthetic used to provide pain relief. Used for Mouth pain relief.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BBC oral spray |
|---|---|
| Sponsor | Hams Hamed Abdelrahman |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 2 |
Mechanism of action
It works by blocking the production of substance P, a chemical involved in transmitting pain signals to the brain. This results in a numbing effect on the affected area, providing temporary pain relief.
Approved indications
- Mouth pain relief
Common side effects
- Burning sensation
- Tingling sensation
Key clinical trials
- N Acetylcystene in Treatment of Radiotherapy Induced Oral Mucositis in Oral Cancer Patients (NA)
- Adjunctive Treatments for the Prevention of Radiotherapy-Induced Mucositis (NA)
- Effectiveness of Photo-biomodulation in the Treatment of Chemotherapy Induced Mucositis (NA)
- Topical Chamomile in Preventing Chemotherapy-induced Oral Mucositis (PHASE2)
- Vitamin D Oral Gel for Prevention of Radiation Induced Oral Mucositis (PHASE2)
- Melatonin for Prevention of Radiation Induced Oral Mucositis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BBC oral spray CI brief — competitive landscape report
- BBC oral spray updates RSS · CI watch RSS
- Hams Hamed Abdelrahman portfolio CI
Frequently asked questions about BBC oral spray
What is BBC oral spray?
How does BBC oral spray work?
What is BBC oral spray used for?
Who makes BBC oral spray?
What development phase is BBC oral spray in?
What are the side effects of BBC oral spray?
Related
- Manufacturer: Hams Hamed Abdelrahman — full pipeline
- Therapeutic area: All drugs in Pain management
- Indication: Drugs for Mouth pain relief
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing